Understanding the pharmacogenetics of selective serotonin reuptake inhibitors

Bibliography

• Mark TL. For what diagnoses are psychotropic medications being prescribed? A nationally representative survey of physicians. CNS Drugs 2010;24:319-26
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009;66:848-56
   PubMed Web of Science ®Google Scholar
• Fabbri C, Di Girolamo G, Serretti A. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet 2013;162B:487-520
   PubMed Web of Science ®Google Scholar
• Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1575-86
   PubMed Web of Science ®Google Scholar
• Tansey KE, Guipponi M, Hu X, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 2013;73:679-82
   PubMed Web of Science ®Google Scholar
• Broad., Institute. Ricopili. 2014. Available from: www.broadinstitute.org/mpg/ricopili [Last accessed 12 May 2014]
   Google Scholar
• GENDEP; Mars; Star D. I. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 2013;170:207-17
   PubMed Web of Science ®Google Scholar
• Montojo J, Zuberi K, Rodriguez H, et al. GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics 2010;26:2927-8
   PubMed Web of Science ®Google Scholar
• Demchak B, Ono K, Hull T, et al. Cytoscape. 2014. Available from: www.cytoscape.org/ [ Last accessed 12 May 2014]
   Google Scholar
• Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2007;21:461-71
   PubMed Web of Science ®Google Scholar
• Porcelli S, Drago A, Fabbri C, Serretti A. Mechanisms of antidepressant action: an integrated dopaminergic perspective. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1532-43
   PubMed Web of Science ®Google Scholar
• Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012;22:239-58
   PubMed Web of Science ®Google Scholar
• Long H, Liu B, Hou B, et al. The long rather than the short allele of 5-HTTLPR predisposes Han Chinese to anxiety and reduced connectivity between prefrontal cortex and amygdala. Neurosci Bull 2013;29:4-15
   PubMed Web of Science ®Google Scholar
• Myung W, Lim SW, Kim S, et al. Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology (Berl) 2013;225:283-90
   PubMed Web of Science ®Google Scholar
• Kato M, Nonen S, Serretti A, et al. 5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial. J Clin Psychopharmacol 2013;33:131-2
   PubMed Web of Science ®Google Scholar
• Smits KM, Smits LJ, Peeters FP, et al. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet 2008;18:184-90
   PubMed Web of Science ®Google Scholar
• Gressier F, Bouaziz E, Verstuyft C, et al. 5-HTTLPR modulates antidepressant efficacy in depressed women. Psychiatr Genet 2009;19:195-200
   PubMed Web of Science ®Google Scholar
• Perna G, Favaron E, Di Bella D, et al. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology 2005;30:2230-5
   PubMed Web of Science ®Google Scholar
• Pitychoutis PM, Zisaki A, Dalla C, Papadopoulou-Daifoti Z. Pharmacogenetic insights into depression and antidepressant response: does sex matter? Curr Pharm Des 2010;16:2214-23
   PubMed Web of Science ®Google Scholar
• Rodriguez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer’s disease. Prog Neurobiol 2012;99:15-41
   PubMed Web of Science ®Google Scholar
• Murphy GM Jr, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004;61:1163-9
   PubMed Web of Science ®Google Scholar
• Shiroma PR, Drews MS, Geske JR, Mrazek DA. SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. Am J Geriatr Psychiatry 2013. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Murphy CF, Gunning-Dixon FM, et al. Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression. J Affect Disord 2009;119:132-41
   PubMed Web of Science ®Google Scholar
• Hu XZ, Rush AJ, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007;64:783-92
   PubMed Web of Science ®Google Scholar
• Maron E, Tammiste A, Kallassalu K, et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol 2009;19:451-6
   PubMed Web of Science ®Google Scholar
• Perlis RH, Mischoulon D, Smoller JW, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003;54:879-83
   PubMed Web of Science ®Google Scholar
• Popp J, Leucht S, Heres S, Steimer W. Serotonin transporter polymorphisms and side effects in antidepressant therapy – a pilot study. Pharmacogenomics 2006;7:159-66
   PubMed Web of Science ®Google Scholar
• Smits K, Smits L, Peeters F, et al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 2007;22:137-43
   PubMed Web of Science ®Google Scholar
• Strohmaier J, Wust S, Uher R, et al. Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. World J Biol Psychiatry 2011;12:528-38
   PubMed Web of Science ®Google Scholar
• Biernacka JM, McElroy SL, Crow S, et al. Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. J Affect Disord 2012;136:e21-9
   Google Scholar
• Gudayol-Ferre E, Herrera-Guzman I, Camarena B, et al. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. J Affect Disord 2010;127:343-51
   PubMed Web of Science ®Google Scholar
• Kraft JB, Slager SL, McGrath PJ, Hamilton SP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 2005;58:374-81
   PubMed Web of Science ®Google Scholar
• Ruhe HG, Ooteman W, Booij J, et al. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenet Genomics 2009;19:67-76
   PubMed Web of Science ®Google Scholar
• Staeker J, Leucht S, Laika B, Steimer W. Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. Genet Test Mol Biomarkers 2014;18:20-31
   PubMed Web of Science ®Google Scholar
• Dreimuller N, Tadic A, Dragicevic A, et al. The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression. Pharmacopsychiatry 2012;45(3):108-13
   PubMed Web of Science ®Google Scholar
• Gudayol-Ferre E, Herrera-Guzman I, Camarena B, et al. Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms. Hum Psychopharmacol 2012;27:577-86
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000;5:32-8
   PubMed Web of Science ®Google Scholar
• Smeraldi E, Serretti A, Artioli P, et al. Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatr Genet 2006;16:153-8
   PubMed Web of Science ®Google Scholar
• Huezo-Diaz P, Uher R, Smith R, et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 2009;195:30-8
   PubMed Web of Science ®Google Scholar
• Dogan O, Yuksel N, Ergun MA, et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test 2008;12:225-31
   PubMedGoogle Scholar
• Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006;6:27-33
   PubMed Web of Science ®Google Scholar
• Ito K, Yoshida K, Sato K, et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 2002;111:235-9
   PubMed Web of Science ®Google Scholar
• Kim H, Lim SW, Kim S, et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA 2006;296:1609-18
   PubMed Web of Science ®Google Scholar
• Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000;11:215-19
   PubMed Web of Science ®Google Scholar
• Min W, Li T, Ma X, et al. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology (Berl) 2009;205:409-17
   PubMed Web of Science ®Google Scholar
• Bozina N, Peles AM, Sagud M, et al. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J Biol Psychiatry 2008;9:190-7
   PubMed Web of Science ®Google Scholar
• Mrazek DA, Rush AJ, Biernacka JM, et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2009;150B:341-51
   PubMed Web of Science ®Google Scholar
• Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010;15:473-500
   PubMed Web of Science ®Google Scholar
• Takahashi H, Yoshida K, Ito K, et al. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol 2002;12:477-81
   PubMed Web of Science ®Google Scholar
• Wilkie MJ, Smith G, Day RK, et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J 2009;9:61-70
   PubMed Web of Science ®Google Scholar
• Oved K, Morag A, Pasmanik-Chor M, et al. Genome-wide expression profiling of human lymphoblastoid cell lines implicates integrin beta-3 in the mode of action of antidepressants. Transl Psychiatry 2013;3:e313
   PubMed Web of Science ®Google Scholar
• Serretti A, Artioli P, Lorenzi C, et al. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol 2004;7:453-60
   PubMed Web of Science ®Google Scholar
• Villafuerte SM, Vallabhaneni K, Sliwerska E, et al. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet 2009;19:281-91
   PubMed Web of Science ®Google Scholar
• Yu YW, Tsai SJ, Liou YJ, et al. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol 2006;16:498-503
   PubMed Web of Science ®Google Scholar
• Peters EJ, Slager SL, McGrath PJ, et al. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004;9:879-89
   PubMed Web of Science ®Google Scholar
• Levin GM, Bowles TM, Ehret MJ, et al. Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol Diagn Ther 2007;11:155-60
   PubMed Web of Science ®Google Scholar
• Illi A, Setala-Soikkeli E, Viikki M, et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009;20:1125-8
   PubMed Web of Science ®Google Scholar
• Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:183-94
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Sawamura K, Someya T. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacoeconomics J 2004;4:283-6
   PubMed Web of Science ®Google Scholar
• Ferres-Coy A, Santana N, Castane A, et al. Acute 5-HT(1)A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions. Psychopharmacology (Berl) 2013;225:61-74
   PubMed Web of Science ®Google Scholar
• Perroud N, Bondolfi G, Uher R, et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 2011;12:365-77
   PubMed Web of Science ®Google Scholar
• McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78:804-14
   PubMed Web of Science ®Google Scholar
• Peters EJ, Slager SL, Jenkins GD, et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 2009;19:1-10
   PubMed Web of Science ®Google Scholar
• Uher R, Huezo-Diaz P, Perroud N, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009;9:225-33
   PubMed Web of Science ®Google Scholar
• Kishi T, Yoshimura R, Kitajima T, et al. HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Med 2010;12(3):237-42
   PubMed Web of Science ®Google Scholar
• Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 2007;164:1181-8
   PubMed Web of Science ®Google Scholar
• Fabbri C, Drago A, Serretti A. Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR()D. Eur Neuropsychopharmacol 2013;23(7):612-21
   PubMed Web of Science ®Google Scholar
• Cusin C, Serretti A, Zanardi R, et al. Influence of monoamine oxydase A and serotonin receptor 2A polymorphisms in SSRIs antidepressant activity. Int J Neuropsychopharmacol 2002;5:27-35
   PubMed Web of Science ®Google Scholar
• Sato K, Yoshida K, Takahashi H, et al. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002;46:136-40
   PubMed Web of Science ®Google Scholar
• Arias B, Fabbri C, Gressier F, et al. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. Neuropsychobiology 2013;67:41-7
   PubMed Web of Science ®Google Scholar
• Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160:1830-5
   PubMed Web of Science ®Google Scholar
• Bishop JR, Moline J, Ellingrod VL, et al. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006;31:2281-8
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 2006;31:825-31
   PubMed Web of Science ®Google Scholar
• Kato M, Fukuda T, Wakeno M, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006;53:186-95
   PubMed Web of Science ®Google Scholar
• Yoshida K, Naito S, Takahashi H, et al. Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology 2003;48:10-13
   PubMed Web of Science ®Google Scholar
• Tanaka M, Kobayashi D, Murakami Y, et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008;11:261-7
   PubMed Web of Science ®Google Scholar
• Lenze EJ, Dixon D, Nowotny P, et al. Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors. Int J Neuropsychopharmacol 2013;16:279-88
   PubMed Web of Science ®Google Scholar
• Cooper JM, Newby DA, Whyte IM, et al. Serotonin toxicity from antidepressant overdose and its association with the T102C polymorphism of the 5-HT receptor. Pharmacogenomics J 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Serretti A, Zanardi R, Cusin C, et al. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 2001;11:375-80
   PubMed Web of Science ®Google Scholar
• Serretti A, Zanardi R, Rossini D, et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001;6:586-92
   PubMed Web of Science ®Google Scholar
• Ham BJ, Lee BC, Paik JW, et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:104-7
   PubMed Web of Science ®Google Scholar
• Yoshida K, Naito S, Takahashi H, et al. Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1279-83
   PubMed Web of Science ®Google Scholar
• Kato M, Wakeno M, Okugawa G, et al. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. Neuropsychobiology 2007;56:167-71
   PubMed Web of Science ®Google Scholar
• Secher A, Bukh J, Bock C, et al. Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1. Int Clin Psychopharmacol 2009;24:199-203
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Brockmoller J, Roots I, Kirchheiner J. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet Genomics 2008;18:495-506
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Hong CJ, Liou YJ, et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:637-41
   PubMed Web of Science ®Google Scholar
• Rotberg B, Kronenberg S, Carmel M, et al. Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. J Child Adolesc Psychopharmacol 2013;23:117-22
   PubMed Web of Science ®Google Scholar
• Benedetti F, Colombo C, Pirovano A, et al. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl) 2009;203:155-60
   PubMed Web of Science ®Google Scholar
• Benedetti F, Dallaspezia S, Colombo C, et al. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur Psychiatry 2010;25:476-8
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Gau YT, Hong CJ, et al. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 2009;113:183-7
   PubMed Web of Science ®Google Scholar
• Gudayol-Ferre E, Guardia-Olmos J, Pero-Cebollero M, et al. Prediction of the time-course pattern of remission in depression by using clinical, neuropsychological, and genetic variables. J Affect Disord 2013;150:1082-90
   PubMed Web of Science ®Google Scholar
• Arias B, Serretti A, Lorenzi C, et al. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 2006;90:251-6
   PubMed Web of Science ®Google Scholar
• Szegedi A, Rujescu D, Tadic A, et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 2005;5:49-53
   PubMed Web of Science ®Google Scholar
• Illi A, Setala-Soikkeli E, Kampman O, et al. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. Psychiatry Res 2010;176:85-7
   PubMed Web of Science ®Google Scholar
• Ji Y, Biernacka J, Snyder K, et al. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Pharmacogenomics J 2012;12:78-85
   PubMed Web of Science ®Google Scholar
• Stein DJ, Daniels WM, Savitz J, Harvey BH. Brain-derived neurotrophic factor: the neurotrophin hypothesis of psychopathology. CNS Spectr 2008;13:945-9
   PubMed Web of Science ®Google Scholar
• Araragi N, Lesch KP. Serotonin (5-HT) in the regulation of depression-related emotionality: insight from 5-HT transporter and tryptophan hydroxylase-2 knockout mouse models. Curr Drug Targets 2013;14:549-70
   PubMed Web of Science ®Google Scholar
• Bath KG, Jing DQ, Dincheva I, et al. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology 2012;37:1297-304
   PubMed Web of Science ®Google Scholar
• Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257-69
   PubMed Web of Science ®Google Scholar
• Govindarajan A, Rao BS, Nair D, et al. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci U S A 2006;103:13208-13
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Cheng CY, Yu YW, et al. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 2003;123B:19-22
   PubMed Web of Science ®Google Scholar
• Yoshida K, Higuchi H, Kamata M, et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol 2007;21:650-6
   PubMed Web of Science ®Google Scholar
• Zou YF, Wang Y, Liu P, et al. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology 2010;61:71-8
   PubMed Web of Science ®Google Scholar
• Choi MJ, Kang RH, Lim SW, et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 2006;1118:176-82
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Glatt CE, Hoptman MJ, et al. BDNF Val66met polymorphism, white matter abnormalities and remission of geriatric depression. J Affect Disord 2010;125(1-3):262-8
   PubMed Web of Science ®Google Scholar
• Murphy GM Jr, Sarginson JE, Ryan HS, et al. BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. Pharmacogenet Genomics 2013;23:301-13
   PubMed Web of Science ®Google Scholar
• Haghighi M, Salehi I, Erfani P, et al. Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only. J Psychiatr Res 2013;47:908-15
   PubMed Web of Science ®Google Scholar
• Tsen P, El Mansari M, Blier P. Effects of repeated electroconvulsive shocks on catecholamine systems: electrophysiological studies in the rat brain. Synapse 2013;67:716-27
   PubMed Web of Science ®Google Scholar
• Dwivedi Y. Involvement of brain-derived neurotrophic factor in late-life depression. Am J Geriatr Psychiatry 2013;21:433-49
   PubMed Web of Science ®Google Scholar
• Domschke K, Lawford B, Laje G, et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol 2010;13:93-101
   PubMed Web of Science ®Google Scholar
• Hennings JM, Kohli MA, Czamara D, et al. Possible associations of NTRK2 polymorphisms with antidepressant treatment outcome: findings from an extended tag SNP approach. PLoS One 2013;8:e64947
   Google Scholar
• Keers R, Bonvicini C, Scassellati C, et al. Variation in GNB3 predicts response and adverse reactions to antidepressants. J Psychopharmacol 2011;25:867-74
   PubMed Web of Science ®Google Scholar
• O’Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol 2012;165:289-312
   PubMed Web of Science ®Google Scholar
• O’Brien FE, O’Connor RM, Clarke G, et al. The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram. Behav Brain Res 2014;261:17-25
   PubMed Web of Science ®Google Scholar
• Kato M, Fukuda T, Serretti A, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:398-404
   PubMed Web of Science ®Google Scholar
• Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res 2008;58:344-7
   PubMed Web of Science ®Google Scholar
• Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008;57:203-9
   PubMed Web of Science ®Google Scholar
• Sarginson JE, Lazzeroni LC, Ryan HS, et al. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 2010;20:467-75
   PubMed Web of Science ®Google Scholar
• Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009;14:1105-18
   PubMed Web of Science ®Google Scholar
• Huang X, Yu T, Li X, et al. ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. Pharmacogenomics 2013;14:1723-30
   PubMed Web of Science ®Google Scholar
• Lin KM, Chiu YF, Tsai IJ, et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 2011;21:163-70
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Eap CB, Oneda B, et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008;30:474-82
   PubMed Web of Science ®Google Scholar
• Mihaljevic Peles A, Bozina N, Sagud M, et al. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1439-44
   PubMed Web of Science ®Google Scholar
• Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 2008;3:e1872
   PubMed Web of Science ®Google Scholar
• Singh AB, Bousman CA, Ng CH, et al. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry 2012;2:e198
   PubMed Web of Science ®Google Scholar
• Breitenstein B, Scheuer S, Pfister H, et al. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. CNS Spectr 2014;19(2):165-75
   PubMed Web of Science ®Google Scholar
• de Klerk OL, Nolte IM, Bet PM, et al. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J 2013;13(4):349-53
   PubMed Web of Science ®Google Scholar
• Zourkova A, Slanar O, Jarkovsky J, et al. MDR1 in paroxetine-induced sexual dysfunction. J Sex Marital Ther 2013;39:71-8
   PubMed Web of Science ®Google Scholar
• Noordam R, Aarts N, Hofman A, et al. Association between genetic variation in the ABCB1 gene and switching, discontinuation, and dosage of antidepressant therapy: results from the Rotterdam Study. J Clin Psychopharmacol 2013;33:546-50
   PubMed Web of Science ®Google Scholar
• Porcelli S, Fabbri C, Spina E, et al. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol 2011;7:1101-15
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104:173-92
   PubMed Web of Science ®Google Scholar
• Winner J, Allen JD, Altar CA, Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry 2013;3:e242
   PubMed Web of Science ®Google Scholar
• Krystal JH, Sanacora G, Blumberg H, et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 2002;7(Suppl 1):S71-80
   PubMedGoogle Scholar
• Ampuero E, Stehberg J, Gonzalez D, et al. Repetitive fluoxetine treatment affects long-term memories but not learning. Behav Brain Res 2013;247:92-100
   PubMed Web of Science ®Google Scholar
• Catches JS, Xu J, Contractor A. Genetic ablation of the GluK4 kainate receptor subunit causes anxiolytic and antidepressant-like behavior in mice. Behav Brain Res 2012;228:406-14
   PubMed Web of Science ®Google Scholar
• Pu M, Zhang Z, Xu Z, et al. Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response. Pharmacogenomics 2013;14:277-88
   PubMed Web of Science ®Google Scholar
• Pickard BS, Malloy MP, Christoforou A, et al. Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol Psychiatry 2006;11:847-57
   PubMed Web of Science ®Google Scholar
• Perlis RH, Laje G, Smoller JW, et al. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 2009;34:1819-28
   PubMed Web of Science ®Google Scholar
• Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007;164:1530-8
   PubMed Web of Science ®Google Scholar
• Li SX, Liu LJ, Xu LZ, et al. Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment. Psychoneuroendocrinology 2013;38:2789-99
   PubMed Web of Science ®Google Scholar
• Rotzinger S, Lovejoy DA, Tan LA. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides 2010;31:736-56
   PubMed Web of Science ®Google Scholar
• Kloiber S, Ripke S, Kohli MA, et al. Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels. Eur Neuropsychopharmacol 2013;23:653-62
   PubMed Web of Science ®Google Scholar
• Picciotto MR, Brabant C, Einstein EB, et al. Effects of galanin on monoaminergic systems and HPA axis: potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors. Brain Res 2010;1314:206-18
   PubMed Web of Science ®Google Scholar
• Kuteeva E, Wardi T, Lundstrom L, et al. Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level. Neuropsychopharmacology 2008;33:2573-85
   PubMed Web of Science ®Google Scholar
• Lu XY, Kim CS, Frazer A, Zhang W. Leptin: a potential novel antidepressant. Proc Natl Acad Sci U S A 2006;103:1593-8
   PubMed Web of Science ®Google Scholar
• Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004;38:213-24
   PubMed Web of Science ®Google Scholar
• Nikisch G, Agren H, Eap CB, et al. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol 2005;8:403-10
   PubMed Web of Science ®Google Scholar
• Zhou Z, Zhu G, Hariri AR, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008;452:997-1001
   PubMed Web of Science ®Google Scholar
• Domschke K, Dannlowski U, Hohoff C, et al. Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol 2010;20:301-9
   PubMed Web of Science ®Google Scholar
• Murck H, Held K, Ziegenbein M, et al. Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. Psychoneuroendocrinology 2004;29:1205-11
   PubMed Web of Science ®Google Scholar
• Unschuld PG, Ising M, Roeske D, et al. Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response. Neuropsychopharmacology 2010;35:1583-92
   PubMed Web of Science ®Google Scholar
• Dryden S, Brown M, King P, Williams G. Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine. Horm Metab Res 1999;31:363-6
   PubMed Web of Science ®Google Scholar
• Kraus T, Haack M, Schuld A, et al. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002;35:220-5
   PubMed Web of Science ®Google Scholar
• Fatseas M, Denis C, Lavie E, Auriacombe M. Relationship between anxiety disorders and opiate dependence – a systematic review of the literature: implications for diagnosis and treatment. J Subst Abuse Treat 2010;38:220-30
   PubMed Web of Science ®Google Scholar
• Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 2006;63:1199-208
   PubMed Web of Science ®Google Scholar
• Garriock HA, Tanowitz M, Kraft JB, et al. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry 2010;167:565-73
   PubMed Web of Science ®Google Scholar
• Cooper AJ, Rickels K, Lohoff FW. Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder. Hum Psychopharmacol 2013;28:258-62
   PubMed Web of Science ®Google Scholar
• Heurteaux C, Lucas G, Guy N, et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci 2006;9:1134-41
   PubMed Web of Science ®Google Scholar
• Dillon DG, Bogdan R, Fagerness J, et al. Variation in TREK1 gene linked to depression-resistant phenotype is associated with potentiated neural responses to rewards in humans. Hum Brain Mapp 2010;31:210-21
   PubMed Web of Science ®Google Scholar
• Perlis RH, Moorjani P, Fagerness J, et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology 2008;33:2810-19
   PubMed Web of Science ®Google Scholar
• Biel M, Wahl-Schott C, Michalakis S, Zong X. Hyperpolarization-activated cation channels: from genes to function. Physiol Rev 2009;89:847-85
   PubMed Web of Science ®Google Scholar
• Nolan MF, Malleret G, Dudman JT, et al. A behavioral role for dendritic integration: HCN1 channels constrain spatial memory and plasticity at inputs to distal dendrites of CA1 pyramidal neurons. Cell 2004;119:719-32
   PubMed Web of Science ®Google Scholar
• Lewis AS, Vaidya SP, Blaiss CA, et al. Deletion of the hyperpolarization-activated cyclic nucleotide-gated channel auxiliary subunit TRIP8b impairs hippocampal Ih localization and function and promotes antidepressant behavior in mice. J Neurosci 2011;31:7424-40
   PubMed Web of Science ®Google Scholar
• Kim CS, Chang PY, Johnston D. Enhancement of dorsal hippocampal activity by knockdown of HCN1 channels leads to anxiolytic- and antidepressant-like behaviors. Neuron 2012;75:503-16
   PubMed Web of Science ®Google Scholar
• Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010;25:201-15
   PubMed Web of Science ®Google Scholar
• Kehne JH. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol Disord Drug Targets 2007;6:163-82
   PubMedGoogle Scholar
• Liu Z, Zhu F, Wang G, et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 2007;414:155-8
   PubMed Web of Science ®Google Scholar
• Licinio J, O’Kirwan F, Irizarry K, et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 2004;9:1075-82
   PubMed Web of Science ®Google Scholar
• Papiol S, Arias B, Gasto C, et al. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 2007;104:83-90
   PubMed Web of Science ®Google Scholar
• Binder EB, Owens MJ, Liu W, et al. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry 2010;67:369-79
   PubMed Web of Science ®Google Scholar
• Brouwer JP, Appelhof BC, van Rossum EF, et al. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 2006;31:1154-63
   PubMed Web of Science ®Google Scholar
• Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry 2008;63:1103-10
   PubMed Web of Science ®Google Scholar
• Ellsworth KA, Moon I, Eckloff BW, et al. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics 2013;23:156-66
   PubMed Web of Science ®Google Scholar
• Brent D, Melhem N, Ferrell R, et al. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 2010;167:190-7
   PubMed Web of Science ®Google Scholar
• Cattaneo A, Gennarelli M, Uher R, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ’predictors’ and longitudinal ’targets’. Neuropsychopharmacology 2013;38:377-85
   PubMed Web of Science ®Google Scholar
• Yu YW, Chen TJ, Hong CJ, et al. Association Study of the Interleukin-1beta (C-511T) Genetic Polymorphism with Major Depressive Disorder, Associated Symptomatology, and Antidepressant Response. Neuropsychopharmacology 2003;28:1182-5
   PubMed Web of Science ®Google Scholar
• Tadic A, Rujescu D, Muller MJ, et al. Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatr Dis Treat 2008;4:269-76
   PubMedGoogle Scholar
• Lin PI, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: the flip-flop phenomenon. Am J Hum Genet 2007;80:531-8
   PubMed Web of Science ®Google Scholar
• Shen X, Carlborg O. Beware of risk for increased false positive rates in genome-wide association studies for phenotypic variability. Front Genet 2013;4:93
   PubMedGoogle Scholar
• Garriock HA, Kraft JB, Shyn SI, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010;67:133-8
   PubMed Web of Science ®Google Scholar
• Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010;167:555-64
   PubMed Web of Science ®Google Scholar
• Crumbley C, Wang Y, Kojetin DJ, Burris TP. Characterization of the core mammalian clock component, NPAS2, as a REV-ERBalpha/RORalpha target gene. J Biol Chem 2010;285:35386-92
   PubMed Web of Science ®Google Scholar
• Perroud N, Uher R, Ng MY, et al. Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics J 2012;12:68-77
   PubMed Web of Science ®Google Scholar
• Laje G, Allen AS, Akula N, et al. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics 2009;19:666-74
   PubMed Web of Science ®Google Scholar
• Holmans P. Statistical methods for pathway analysis of genome-wide data for association with complex genetic traits. Adv Genet 2010;72:141-79
   PubMed Web of Science ®Google Scholar
• Zorumski CF, Paul SM, Izumi Y, et al. Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev 2013;37:109-22
   PubMed Web of Science ®Google Scholar
• Tansey KE, Guipponi M, Perroud N, et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 2012;9:e1001326
   PubMed Web of Science ®Google Scholar
• Serretti A, Olgiati P, Bajo E, et al. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry 2011;12:501-15
   PubMed Web of Science ®Google Scholar
• Olgiati P, Bajo E, Bigelli M, et al. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry 2012;36:147-54
   PubMed Web of Science ®Google Scholar
• Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-11
   PubMed Web of Science ®Google Scholar
• Zanardi R, Benedetti F, DiBella D, et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol 2000;20:105-7
   PubMed Web of Science ®Google Scholar
• Zanardi R, Serretti A, Rossini D, et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001;50:323-30
   PubMed Web of Science ®Google Scholar
• Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression. Neuropsychopharmacology 2000;23:587-90
   PubMed Web of Science ®Google Scholar
• Arias B, Catalan R, Gasto C, et al. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003;23:563-7
   PubMed Web of Science ®Google Scholar
• Durham LK, Webb SM, Milos PM, et al. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004;174:525-9
   PubMed Web of Science ®Google Scholar
• Serretti A, Cusin C, Rossini D, et al. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet 2004;129:36-40
   Google Scholar
• Lotrich FE, Pollock BG, Kirshner M, et al. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci 2008;33:123-30
   PubMed Web of Science ®Google Scholar
• Illi A, Poutanen O, Setala-Soikkeli E, et al. Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? Eur Arch Psychiatry Clin Neurosci 2011;261:95-102
   PubMed Web of Science ®Google Scholar
• Rausch JL, Johnson ME, Fei Y, et al. Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome. Biol Psychiatry 2002;51:723-32
   PubMed Web of Science ®Google Scholar
• Yu YW, Tsai SJ, Chen TJ, et al. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002;7:1115-19
   PubMed Web of Science ®Google Scholar
• Mushtaq D, Ali A, Margoob MA, et al. Association between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder. J Affect Disord 2012;136:955-62
   PubMed Web of Science ®Google Scholar
• Yoshida K, Ito K, Sato K, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:383-6
   PubMed Web of Science ®Google Scholar
• Umene-Nakano W, Yoshimura R, Ueda N, et al. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol 2010;24(12):1764-71
   PubMed Web of Science ®Google Scholar
• Saeki Y, Watanabe T, Ueda M, et al. Genetic and pharmacokinetic factors affecting the initial pharmacotherapeutic effect of paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol 2009;65:685-91
   PubMed Web of Science ®Google Scholar
• Won ES, Chang HS, Lee HY, et al. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder. Neuropsychobiology 2012;66:221-9
   PubMed Web of Science ®Google Scholar
• Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L. Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J 2002;2:176-81
   PubMedGoogle Scholar
• Ng C, Sarris J, Singh A, et al. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum Psychopharmacol 2013;28:516-22
   PubMed Web of Science ®Google Scholar
• Ishiguro S, Watanabe T, Ueda M, et al. Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol 2011;67:1213-21
   PubMed Web of Science ®Google Scholar
• Kim W, Choi YH, Yoon KS, et al. Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1413-18
   PubMed Web of Science ®Google Scholar
• Yevtushenko OO, Oros MM, Reynolds GP. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord 2010;123:308-11
   PubMed Web of Science ®Google Scholar
• Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 2007;68:747-53
   PubMed Web of Science ®Google Scholar